The next evolution of
biomanufacturing
We deliver the next generation of bioprocess technologies by leveraging the strengths of process intensification and chaining
Life Science evolves.
Donaldson solves.
Univercells Technologies is part of Donaldson and its focus on Life Sciences and Bioprocessing.
Products
We design innovative cost-
effective manufacturing solutions
scale-X™ bioreactor
Intensified fixed-bed technology for
cost-effective & scalable viral production
NevoLine™ Upstream platform
Integrated & automated solution
for intensified virus manufacturing
Publications
Leveraging small-scale parallel bioreactor systems for reliable and scalable processing design
Our Product Manager Clément Dumont explains how an innovative fixed-bed small-scale parallel system will revolutionize process design & optimization steps resulting in an increased production capacity & quality.
Download
Suspension-based viral vector production in scale-X fixed-bed bioreactor
Shake flask process transferred in a scale-X hydro fixed-bed bioreactor for Adenovirus production with HEK293 cells adapted to suspension.
Learn more
Integrated continuous biomass estimation in fixed-bed bioreactors
Novel approach allows for real-time measurement of cell density in fixed-bed bioreactors
Learn moreCustomer experiences that are built to last
We support your manufacturing success
Vive – Testimonial
For us as a CDMO fully focused on the development and manufacture of lentiviral vectors according to both the FDA´s and EMA´s standards, the main advantages of Univercells Technologies bioreactors are both the high level of process control and the very good coverage of the production requirements for the different phases from development to commercial with their well-established intermediate scales
Visit siteAranguren
Director of Operations – VIVEBiotech
Exothera – Testimonial
scale-X technology is a well-designed, efficient, and easy scalable family of bioreactors that showed its value in many of Exothera’s projects. We couldn’t desire for a better solution to support our clients and provide the best services in the fast-growing CGT market.
Visit siteHanna Lesch
Chief Technology Officer – Exothera
From 37 answers over 16 months
Newsroom
Designed to operate both the 200 and 600 m² scale-X nitro bioreactors, the new controller, as part of the scale-X platform, offers a cost-effective, low-footprint and user-friendly solution for large-scale viral and advanced therapy manufacturing
Read article “Univercells Technologies debuts the scale-X™ nitro controller to expand access to large-scale viral and advanced therapy manufacturing”
The scale-X nexo accelerated and facilitated the CER’s process development journey, with reduced COGs due to its small surface and volume.
Read article “CER Groupe uses scale-X™ nexo bioreactor for efficient early-stage development”